CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited has announced the successful drug registration approval of its Olaparib Tablets, used in the treatment of various types of ovarian cancer, by the National Medical Products Administration of China. This milestone marks a significant expansion of the Group’s oncology product portfolio. Olaparib is recognized by leading cancer treatment guidelines and is now poised to make an impact in the Chinese pharmaceutical market.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
